Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Inflammation and the immune system

Topic: Amyloid, tau and blood-test diagnosis

The protein composition of tear fluid (TF) reflects the severity and progression of many age-related diseases. Here, we evaluated TF proteins from patients with mild Alzheimer's disease (AD) and cognitively healthy controls (CO) to explore potential new biomarker molecules. The aim of this study was to explore potential new biomarker molecules by examining the expression of TF proteins whose function is related to neuroinflammation. We examined 53 participants (34 COs, mean age 71 years, Mini-Mental State Examination (MMSE) score 28.9 ± 1.4; 19 with AD, Clinical Dementia Rating 0.5-1, mean age 72 years, MMSE 23.8 ± 2.8). All participants underwent neurological status examination, cognitive testing, and ophthalmological examination. TF was collected using Schirmer strips, and TF protein content was evaluated using mass spectrometry-based proteomics and label-free quantification. We report 14 TF proteins that showed altered protein expression in the AD group compared to the CO group. Twelve proteins were significantly upregulated (SERPINA3, FGA, SIAS, ORM1, ANXA3, G6PI/NLK, CH3L2, MSLN, CPPED1, JCHAIN, IGHV5-51, SPARCL1) and two were downregulated (PIP, SCGB2A1) (p ≤ 0.05). Observed altered expression of TF proteins in the AD group may have potential in AD pathology. Since inflammation is one of the earliest signs of neurodegeneration in AD, these proteins are putative new biomarker candidates of early AD.

Key findings

Why it matters

In a small study of 53 people, 14 proteins related to neuroinflammation showed altered levels in tear fluid from those with mild Alzheimer's disease compared with healthy controls. This is biomarker research only and does not show that measuring these proteins can treat, cure or prevent the disease.

Study details

How this study scored 42/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 1 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multi-centre collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 42 of 100.42 of 100 points earned58 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Molecular Neuroscience)
Journal's citation record 1 / 4 Journal of Molecular Neuroscience: journal h-index 118 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 1 / 4 53 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 4 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.3 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 2.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Tor Paaske Utheim: h-index 48 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Helsinki: institution h-index 1,201 (OpenAlex)
Multi-centre collaboration 3 / 3 OpenAlex lists 12 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40471493)
Free to read 2 / 2 Free to read
Total 42 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Kärkkäinen, V., Saari, T. T., Rusanen, M., Uusitalo, H. M. T., Leinonen, V., Thiede, B., et al. (2025). Neuroinflammation Markers in Tear Fluid of Mild Alzheimer’s Disease. Journal of Molecular Neuroscience. https://doi.org/10.1007/s12031-025-02368-x

Vancouver

Kärkkäinen V, Saari TT, Rusanen M, Uusitalo HMT, Leinonen V, Thiede B, et al. Neuroinflammation Markers in Tear Fluid of Mild Alzheimer’s Disease. Journal of Molecular Neuroscience. 2025. doi:10.1007/s12031-025-02368-x. PMID: 40471493.

BibTeX

@article{karkkainen2025-40471493,
  author  = {Kärkkäinen, Virve and Saari, Toni Tapani and Rusanen, Minna and Uusitalo, Hannu M. T. and Leinonen, Ville and Thiede, Bernd and Kaarniranta, Kai and Koivisto, Anne Maria and others},
  title   = {{Neuroinflammation Markers in Tear Fluid of Mild Alzheimer’s Disease}},
  journal = {Journal of Molecular Neuroscience},
  year    = {2025},
  doi     = {10.1007/s12031-025-02368-x},
  pmid    = {40471493},
  url     = {https://doi.org/10.1007/s12031-025-02368-x}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Inflammation and the immune system

Also tagged “biomarkers”

821 studies in the library carry the topic tag “biomarkers”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.

Similar studies

More on Inflammation and the immune system

See all studies in Inflammation and the immune system →